U.S. Centers for Disease Control and Prevention. About type 2 diabetes. 2024. https://www.cdc.gov/diabetes/about/about-type-2-diabetes.html?CDC_AAref_Val=https://www.cdc.gov/diabetes/basics/type2.html. Accessed 30 May 2024.

Zhuo X, Zhang P, Hoerger TJ. Lifetime direct medical costs of treating type 2 diabetes and diabetic complications. Am J Prev Med. 2013;45:253–61.

PubMed  Google Scholar 

American Diabetes Association. Economic costs of diabetes in the U.S. in 2017. Diabetes Care. 2018;41:917–28.

PubMed Central  Google Scholar 

Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–89.

CAS  PubMed  Google Scholar 

American Diabetes Association (ADA) Professional Practice Committee. Obesity and weight management for the prevention and treatment of type 2 diabetes standards of care in diabetes-2024. Diabetes Care. 2024;47:S145–57.

Google Scholar 

American Diabetes Association Professional Practice Committee. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2024. Diabetes Care. 2024;47:S158–78.

Google Scholar 

Shaefer CF Jr, Kushner P, Aguilar R. User’s guide to mechanism of action and clinical use of GLP-1 receptor agonists. Postgrad Med. 2015;127:818–26.

PubMed  Google Scholar 

Novo Nordisk. Ozempic Prescribing Information. 2023. https://www.novo-pi.com/ozempic.pdf. Accessed 04 June 2024.

Hsia DS, Grove O, Cefalu WT. An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus. Curr Opin Endocrinol Diabetes Obes. 2017;24:73–9.

CAS  PubMed  PubMed Central  Google Scholar 

Shah M, Vella A. Effects of GLP-1 on appetite and weight. Rev Endocr Metab Disord. 2014;15:181–7.

CAS  PubMed  PubMed Central  Google Scholar 

Pereira MJ, Eriksson JW. Emerging role of SGLT-2 inhibitors for the treatment of obesity. Drugs. 2019;79:219–30.

CAS  PubMed  PubMed Central  Google Scholar 

Husain M, Bain SC, Jeppesen OK, et al. Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk. Diabetes Obes Metab. 2020;22:442–51.

PubMed  PubMed Central  Google Scholar 

de Havenon A, Tan X, Liang Y, et al. Comparing the real-world effects of once-weekly semaglutide and DPP-4is on cardiovascular outcomes, healthcare resource utilization, and medical costs in individuals with T2D and ASCVD. International stroke conference, Phoenix, Arizona; 2024.

Ahrén B, Masmiquel L, Kumar H, et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. Lancet Diabetes Endocrinol. 2017;5:341–54.

PubMed  Google Scholar 

Ahmann AJ, Capehorn M, Charpentier G, et al. Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label randomized clinical trial. Diabetes Care. 2018;41:258–66.

CAS  PubMed  Google Scholar 

Aroda VR, Bain SC, Cariou B, et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. Lancet Diabetes Endocrinol. 2017;5:355–66.

CAS  PubMed  Google Scholar 

Pratley RE, Aroda VR, Lingvay I, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018;6:275–86.

CAS  PubMed  Google Scholar 

Kellerer M, Kaltoft MS, Lawson J, et al. Effect of once-weekly semaglutide versus thrice-daily insulin aspart, both as add-on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11): a randomized, open-label, multinational, phase 3b trial. Diabetes Obes Metab. 2022;24:1788–99.

CAS  PubMed  PubMed Central  Google Scholar 

Lingvay I, Catarig AM, Frias JP, et al. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. Lancet Diabetes Endocrinol. 2019;7:834–44.

CAS  PubMed  Google Scholar 

Sharma R, Wilkinson L, Vrazic H, et al. Comparative efficacy of once-weekly semaglutide and SGLT-2 inhibitors in type 2 diabetic patients inadequately controlled with metformin monotherapy: a systematic literature review and network meta-analysis. Curr Med Res Opin. 2018;34:1595–603.

CAS  PubMed  Google Scholar 

Lingvay I, Kirk AR, Lophaven S, Wolden ML, Shubrook JH. Outcomes in GLP-1 RA-experienced patients switching to once-weekly semaglutide in a real-world setting: the retrospective, observational EXPERT study. Diabetes Ther. 2021;12:879–96.

CAS  PubMed  PubMed Central  Google Scholar 

Rajamand Ekberg N, Bodholdt U, Catarig AM, et al. Real-world use of once-weekly semaglutide in patients with type 2 diabetes: results from the SURE Denmark/Sweden multicentre, prospective, observational study. Prim Care Diabetes. 2021;15:871–8.

CAS  PubMed  Google Scholar 

Rudofsky G, Catarig AM, Favre L, et al. Real-world use of once-weekly semaglutide in patients with type 2 diabetes: results from the SURE Switzerland multicentre, prospective, observational study. Diabetes Res Clin Pract. 2021;178:108931.

CAS  PubMed  Google Scholar 

Holmes P, Bell HE, Bozkurt K, et al. Real-world use of once-weekly semaglutide in type 2 diabetes: results from the SURE UK multicentre, prospective, observational study. Diabetes Ther. 2021;12:2891–905.

CAS  PubMed  PubMed Central  Google Scholar 

Napoli R, Berra C, Catarig AM, et al. Once-weekly semaglutide use in patients with type 2 diabetes: real-world data from the SURE Italy observational study. Diabetes Obes Metab. 2023;25:1658–67.

CAS  PubMed  Google Scholar 

Menzen M, Berentzen TL, Catarig AM, Pieperhoff S, Simon J, Jacob S. Real-world use of once-weekly semaglutide in type 2 diabetes: results from SemaglUtide Real-world Evidence (SURE) Germany. Exp Clin Endocrinol Diabetes. 2023;131:205–15.

CAS  PubMed  PubMed Central  Google Scholar 

Wolffenbuttel BHR, Brugts MP, Catarig AM, et al. Once-weekly semaglutide use in type 2 diabetes: real-world data from the SURE Netherlands observational study. Adv Ther. 2023;40:920–33.

CAS  PubMed  Google Scholar 

Bellido V, Abreu Padín C, Catarig AM, Clark A, Barreto Pittol S, Delgado E. Once-weekly semaglutide use in patients with type 2 diabetes: results from the SURE Spain multicentre, prospective observational study. J Clin Med. 2022;11:4938.

CAS  PubMed  PubMed Central  Google Scholar 

Mohammedi K, Belhatem N, Berentzen TL, Catarig AM, Potier L. Once-weekly semaglutide use in patients with type 2 diabetes: results from the SURE France multicentre, prospective, observational study. Diabetes Obes Metab. 2023;25:1855–64.

CAS  PubMed  Google Scholar 

Yale JF, Catarig AM, Grau K, et al. Use of once-weekly semaglutide in patients with type 2 diabetes in routine clinical practice: results from the SURE Canada multicentre, prospective, observational study. Diabetes Obes Metab. 2021;23:2269–78.

CAS  PubMed  PubMed Central  Google Scholar 

Serpa-Díaz D, Llanos-Florez CA, Uribe RS, et al. Glycemic control and body weight reduction with once-weekly semaglutide in colombian adults with type 2 diabetes: findings from the COLIBRI study. Diabetes Ther. 2024;15:1451–60.

PubMed  PubMed Central  Google Scholar 

Raju A, Pimple P, Stafkey-Mailey D, Farrelly E, Shetty S. Healthcare costs and resource utilization associated with the use of empagliflozin versus other antihyperglycemic agents among patients with type 2 diabetes mellitus and cardiovascular disease: a real-world retrospective cohort analysis. Diabetes Ther. 2022;13:25–42.

CAS  PubMed  Google Scholar 

Code of Federal Regulations. 45 CFR 46.104. 2025. https://www.ecfr.gov/current/title-45/subtitle-A/subchapter-A/part-46/subpart-A/section-46.104. Accessed 13 Feb 2025.

DeSouza C, Cariou B, Garg S, Lausvig N, Navarria A, Fonseca V. Efficacy and safety of semaglutide for type 2 diabetes by race and ethnicity: a post hoc analysis of the SUSTAIN trials. J Clin Endocrinol Metab. 2020;105:dgz072.

PubMed  Google Scholar 

Capehorn MS, Catarig AM, Furberg JK, et al. Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 12mg as add-on to 1–3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 1.0). Diabetes Metab. 2020;46:100–9.

CAS  PubMed  Google Scholar 

Amamoo J, Doshi RP, Noone J, et al. 87-LB: real-world impact of once-weekly injectable semaglutide on glycemic control and weight outcomes in type 2 diabetes (RELATE-OW injectable semaglutide). Diabetes. 2023;72(Suppl_1):87-LB.

Google Scholar 

Guerci B, Chanan N, Kaur S, Jasso-Mosqueda JG, Lew E. Lack of treatment persistence and treatment nonadherence as barriers to glycaemic control in patients with type 2 diabetes. Diabetes Ther. 2019;10:437–49.

PubMed  PubMed Central  Google Scholar 

Bonora BM, Russo G, Leonetti F, et al. Effectiveness of oral semaglutide on glucose control and body weight up to 18 months: a multicenter retrospective real-world study. J Endocrinol Invest. 2024;47:1395–403.

CAS  PubMed  PubMed Central  Google Scholar 

Ding L, Sun B, Xiao X. Comparing the efficacy and safety of glucagon-like peptide 1 receptor agonists with sodium-glucose cotransporter 2 inhibitors for obese type 2 diabetes patients uncontrolled on metformin: a systematic review and meta-analysis of randomized clinical trials. Int J Endocrinol. 2020;2020:1626484.

PubMed  PubMed Central